Patients with DME who are treated using aflibercept are more likely to experience acute kidney injury or hospitalisation due to renal events than those treated with ranibizumab. Using a target trial ...
Among 41 patients treated with 8-mg aflibercept, five developed mild sterile intraocular inflammation within 1 to 3 days. All cases resolved with treatment and caused no permanent vision loss. Early ...
Resveratrol supplementation in wet AMD patients led to fewer aflibercept injections and reduced macular fibrosis progression over two years. Both treatment groups showed significant improvements in ...
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient ...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
Aflibercept 8mg (0.07mL of 114.3mg/mL); per vial; soln for oph intravitreal inj; preservative-free. A single-dose glass vial containing one Eylea HD 8 mg (0.07 mL of a 114.3 mg/mL solution); or A vial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results